Levoin Nicolas, Jean Mickael, Legembre Patrick
Bioprojet Biotech, Saint-Grégoire, France.
Univ Rennes, CNRS, ISCR-UMR 6226, Rennes, France.
Front Cell Dev Biol. 2020 May 5;8:314. doi: 10.3389/fcell.2020.00314. eCollection 2020.
CD95 is a pre-ligand-associated transmembrane (TM) receptor. The interaction with its ligand CD95L brings to a next level its aggregation and triggers different signaling pathways, leading to cell motility, differentiation or cell death. This diversity of biological responses associated with a unique receptor devoid of enzymatic property raises the question of whether different ligands exist, or whether the fine-tuned control of CD95 aggregation and conformation, its distribution within certain plasma membrane sub-domains or the pattern of post-translational modifications account for this such broad-range of cell signaling. Herein, we review how the different domains of CD95 and their post-translational modifications or the different forms of CD95L can participate in the receptor aggregation and induction of cell signaling. Understanding how CD95 response goes from cell death to cell proliferation, differentiation and motility is a prerequisite to reveal novel therapeutic options to treat chronic inflammatory disorders and cancers.
CD95是一种与配体前体相关的跨膜(TM)受体。它与配体CD95L的相互作用使其聚集进入下一阶段,并触发不同的信号通路,从而导致细胞迁移、分化或细胞死亡。这种与缺乏酶活性的独特受体相关的生物反应多样性,引发了这样一个问题:是否存在不同的配体,或者CD95聚集和构象的精细调控、其在某些质膜亚结构域内的分布,还是翻译后修饰模式,导致了如此广泛的细胞信号传导。在此,我们综述了CD95的不同结构域及其翻译后修饰或CD95L的不同形式如何参与受体聚集和细胞信号传导的诱导。了解CD95反应如何从细胞死亡转变为细胞增殖、分化和迁移,是揭示治疗慢性炎症性疾病和癌症新治疗选择的先决条件。